JB Chemicals & Pharmaceuticals Limited

rs,

ironment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company

INR3,918

not be copied or disseminated, in whole or in part, and in any manner. 2 JB Pharma At A Glance INR3,918 Cr 6 Top 5 FY25 Revenue Brands in IPM Top 300 CDMO of Lozenges Globally Scale Domestic Growt

58%

ter excluding non-cash ESOP Charge 3. ROCE = EBIT/(Net Worth + Net Debt - Mutual Fund Investments) 58% Domestic Revenue % (FY25) 1.5x Outperformance vs IPM (MAT Mar’25) 27.7% Operating EBITDA Ma

1.5x

e 3. ROCE = EBIT/(Net Worth + Net Debt - Mutual Fund Investments) 58% Domestic Revenue % (FY25) 1.5x Outperformance vs IPM (MAT Mar’25) 27.7% Operating EBITDA Margin % (FY25) #16 Prescription R

27.7%

tual Fund Investments) 58% Domestic Revenue % (FY25) 1.5x Outperformance vs IPM (MAT Mar’25) 27.7% Operating EBITDA Margin % (FY25) #16 Prescription Rank (FY25) 17% Revenue CAGR (FY22-25) 17

17%

nce vs IPM (MAT Mar’25) 27.7% Operating EBITDA Margin % (FY25) #16 Prescription Rank (FY25) 17% Revenue CAGR (FY22-25) 17% PAT Margin % (FY25) 47% FY25 Chronic %(1) 20% Operating EBITDA CA

47%

in % (FY25) #16 Prescription Rank (FY25) 17% Revenue CAGR (FY22-25) 17% PAT Margin % (FY25) 47% FY25 Chronic %(1) 20% Operating EBITDA CAGR (FY22-25)(2) 32% ROCE (FY25(3) 3 3 Q4 and FY25

20%

iption Rank (FY25) 17% Revenue CAGR (FY22-25) 17% PAT Margin % (FY25) 47% FY25 Chronic %(1) 20% Operating EBITDA CAGR (FY22-25)(2) 32% ROCE (FY25(3) 3 3 Q4 and FY25 Business Performance 4

32%

Y22-25) 17% PAT Margin % (FY25) 47% FY25 Chronic %(1) 20% Operating EBITDA CAGR (FY22-25)(2) 32% ROCE (FY25(3) 3 3 Q4 and FY25 Business Performance 4 CEO’s Message – Q4 FY25 “ We have clos

75%

ne of the fastest growing in IPM. We have built a strong foundation over the last five years. With 75% of India branded formulations sales in progressive, faster-growing segments, we are confident in

69%

back strongly in second half of the year. Together our Domestic and CDMO business now constitute 69% of overall revenues - Both businesses enjoy high ROCEs & high operating margins and contributed st

10%

iews on Q4 FY25 business performance Results Overview: Q4 FY25 vs Q4 FY24 Revenues (INR crores) 10% o JB Pharma recorded revenue growth of 10% to INR 949 862 949 Q4 FY24 Q4 FY25 19 129 Q4 FY

ESG scores for companies are available at

1

ESG scores for companies are available at

https://www.spglobal.com/esg/solutions/esg-scores-data 42 42 About JB Pharma J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | ISIN: INE572A01028), established in 1976, is one of the fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has six brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it in the manufacturing of medicated lozenges. The company ranks amongst the top 5 manufacturers globally in medicated and herbal lozenges. It has eight state of the art manufacturing facilities including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world. is also a lea